Table of Contents
PPT Slide
Safe Harbor
ArQule’s Strategy
Cyclis Mission
Management
Scientific Advisory Board
Discovery & Development: From Target ID to Clinical Trials
Discovery & Development: From Target ID to Clinical Trials
Target Identification And Validation
The ACT Platform
Cell Cycle Checkpoints
ACT - More Selective than Chemotherapy
ACT - Broader Spectrum than Current Targeted Therapy
ACT Platform: Multiple Drug Targets
E2F Mechanism Summary
Cancer Survival Protein (CSP) Program
Inhibition of TF1 Causes Regression of Breast Cancer
p53 Program
p53/PUMA Pathway
Lead Generation and Lead Optimization
Lead Generation - Pfizer Strategic Alliance
Lead Optimization – p38 MAP kinase
p38 MAP Kinase Inhibitors Program for Rheumatoid Arthritis (RA)
Effects of Lead Compound in RA Model: Reduction in Ankle Diameter
Effects of Lead Compound in RA Model: Body Weight Change
R&D Portfolio
Regulatory and Clinical Development
CO-501
Broad Spectrum and High Potency of CO-501
CO-501 Effective in Animal Models of Human Cancer
CO-501 Safety Margin in animal models
CO-501 Development
Financial Terms
Financials
Milestones 2003
Synergies
|